Andrew Hollman Meyer - Sep 27, 2024 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Chief Business Officer
Signature
/s/ James Pennington, Attorney-in-Fact
Stock symbol
JANX
Transactions as of
Sep 27, 2024
Transactions value $
-$2,087,255
Form type
4
Date filed
9/27/2024, 07:32 PM
Previous filing
Jan 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Options Exercise $211K +50K +73.97% $4.21 118K Sep 27, 2024 Direct F1
transaction JANX Common Stock Sale -$2.3M -50K -42.52% $45.96 67.6K Sep 27, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock Option (right to buy) Options Exercise $0 -50K -33.19% $0.00 101K Sep 27, 2024 Common Stock 50K $4.21 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,189 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on November 15, 2021, 1,752 shares acquired under the Plan on May 13, 2022, 2,401 shares acquired under the Plan on May 15, 2023 and 2,834 shares acquired under the Plan on May 15, 2024.
F2 The weighted average sale price for the transaction reported was $45.9551 and the range of prices were between $45.55 and $46.50. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3 Immediately exercisable.